Samia A Shouman
Overview
Explore the profile of Samia A Shouman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ali B, El-Abhar H, Mohamed G, Nassar H, Aliedin N, Sharaky M, et al.
J Steroid Biochem Mol Biol
. 2024 Nov;
245:106636.
PMID: 39536950
The lack of targeted therapy for triple-negative breast cancer (TNBC) is among the mainsprings of its poor prognosis. This study aimed to elucidate the role of the androgen receptor (AR)...
2.
Omran M, Ibrahim A, Abdelfattah R, Moussa H, Shouman S, Hamza M
Leuk Lymphoma
. 2024 Sep;
66(1):123-130.
PMID: 39291898
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge,...
3.
Hamed S, Hassan N, Shouman S, Tohamy T, Fakhry H, Radwan E
Arch Biochem Biophys
. 2024 May;
757:110039.
PMID: 38750921
C1q tumor necrosis factor-related protein 6 (CTRP6), a member of the C1q tumor necrosis factor-related protein (CTRP) family, is reported to be associated with the progression of different malignancies, however,...
4.
Omran M, Ibrahim A, Abdelfattah R, Shouman S, Hamza M
Eur J Clin Pharmacol
. 2024 Mar;
80(7):1061-1068.
PMID: 38536418
Background: Imatinib treatment for certain cancers can lead to elevated creatine kinase (CK) levels, potentially indicating muscle injury, and ongoing research aims to understand the correlation between imatinib levels and...
5.
Abo-Heikal M, El-Shafei J, Shouman S, Roshdy N
Dent Traumatol
. 2023 Aug;
40(1):61-75.
PMID: 37612879
Background/aim: This study aimed at comparing the regenerative potential of injectable platelet-rich fibrin (i-PRF) (Group 1) and platelet-rich plasma (Group 2) scaffolds. Materials And Methods: Twenty-three patients, aged from 9...
6.
Sabri A, Omran M, Azim S, Abdelfattah R, Allam R, Shouman S
Drug Res (Stuttg)
. 2023 Jan;
73(3):146-155.
PMID: 36630991
Imatinib mesylate (IM) is the gold standard for treatment of Chronic Myeloid Leukemia (CML). This study aimed to gain more knowledge of the altered PK, pharmacogenetic factors, and gene expression...
7.
Faid A, Shouman S, Badr Y, Sharaky M, Mostafa E, Sliem M
BMC Chem
. 2022 Nov;
16(1):94.
PMID: 36371236
Background: As a promising strategy to overcome the therapeutic disadvantages of 6-mercaptopurine (6MP), we proposed the encapsulation of 6MP in chitosan nanoparticles (CNPs) to form the 6MP-CNPs complexes. The encapsulation...
8.
Faid A, Shouman S, Badr Y, Sharaky M
BMC Chem
. 2022 Nov;
16(1):90.
PMID: 36352463
Background: The difficulty of achieving targeted drug delivery following administration of presently marketed anticancer therapeutics is still a concern. Metallic nanoparticles (NPs) appear to be promising in this regard. The...
9.
Noureldeen A, Aziz S, Shouman S, Mohamed M, Attia Y, Ramadan R, et al.
Int J Environ Res Public Health
. 2022 Oct;
19(20).
PMID: 36294202
A novel ruthenium(III)-pyrimidine Schiff base was synthesized and characterized using different analytical and spectroscopic techniques. Molecular geometries of the ligand and ruthenium complex were investigated using the DFT-B3LYP level of...
10.
Omran M, Shouman S, Abdelfattah R, Moussa H, Thabet N, Hamza M
Curr Ther Res Clin Exp
. 2022 Oct;
97:100684.
PMID: 36188630
Background: Vitamin D deficiency is a common side effect of imatinib mesylate (IM) therapy. Transporter polypeptides involved in the disposition of IM may be required for maintenance of adequate vitamin...